PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study Academic Article Article uri icon

Overview

MeSH Major

  • Infant, Very Low Birth Weight
  • Leukemoid Reaction

abstract

  • Seattle Genetics.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1016/S1470-2045(15)70013-6

PubMed ID

  • 25683846

Additional Document Info

start page

  • 284

end page

  • 92

volume

  • 16

number

  • 3